Because the full study report of the SIPPET (Survey of Inhibitors in Plasma-Product Exposed Toddlers) results had not been published as of the Saturday, February 27, 2016, meeting of the National Hemophilia Foundation's (NHF's) Medical and Scientific Advisory Council (MASAC), MASAC continues to recommend that families of minimally treated or previously untreated patients (PUPS) discuss the issues surrounding product selection with their hemophilia treater.
As soon as the full study report is published, MASAC will carefully review the data, along with reports from other previously published studies, to determine whether to issue a revised recommendation on the use of recombinant factor products in PUPS.
NHF and MASAC will keep our community updated on this important issue.
